Meta is scrambling to find a “solution” to its Messenger app being unintentionally included in the teen social media ban, in spite of the government’s promise it would be exempt. A seemingly ...
Meta is shutting down its Messenger app for macOS and Windows and pushing users to the web. Meta confirmed over email to Engadget that the app will be fully shutdown on December 15, after which the ...
Meta has published a support doc that states its Messenger app for Mac is being discontinued. New users won’t be able to download the app at all, and existing users have about 60 more days of use ...
Meta is shutting down Messenger’s stand-alone desktop apps for Windows and Mac on December 15, the company confirmed to TechCrunch on Thursday. Starting December 15, users will no longer be able to ...
If you're using Messenger on macOS, you'll want to switch to something else — and probably sooner, rather than later. According to a pair of Facebook Help Center page, Facebook is axing its Desktop ...
Before everyone had a smartphone in their pocket and access to countless free mobile games (both good and hot messes), people got their free gaming fixes from browser games. I have fond memories of ...
On July 22, 2025, Replimune publicly announced that the U.S. Food and Drug Administration (FDA) had issued a "Complete Response Letter" (CRL) for its Biologics License Application (BLA) for RP1. This ...
The fate of a once-promising cancer treatment now looks uncertain at best. The meeting was conducted with U.S. Food and Drug Administration (FDA) officials, and it took place on Tuesday. The subject ...
Messenger is one of the most popular messaging services around, especially in the US, but it has its faults. Group chats, for example, are not end-to-end encrypted by default, meaning the company that ...
When Thongbue Wongbandue began packing to visit a friend in New York City one morning in March, his wife Linda became alarmed. “But you don’t know anyone in the city anymore,” she told him. Bue, as ...
Shares of Replimune (NASDAQ:REPL) plunged ~38% in the premarket on Monday after Stat News reported that the FDA’s top regulator of cancer drugs intervened during the review of the company’s lead asset ...
Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback